CYTK <link back> News 7:32AM Cytokinetics announces initiation of multiple dose Phase I clinical trial of CK-2127107; initiation of this clinical trial triggers a $2 mln milestone payment from Astellas Pharma (ALPMY) to Cytokinetics (CYTK) 8.51 : Co announced the initiation of an additional Phase I clinical trial of CK- 2127107, a fast skeletal muscle troponin activator. The trial, called CY 5012, is a double-blind, randomized, placebo-controlled, parallel group study in which the primary objective is to assess the safety, tolerability, and pharmacokinetics of CK-2127107 following multiple ascending doses in healthy volunteers. The initiation of this clinical trial triggers a $2 mln milestone payment from Astellas Pharma (ALPMY) to Cytokinetics under the terms of the collaboration between the companies established in June 2013.
